Primary HIV infection

Current Infectious Disease Reports

Volumn 6, Issue 1, 2004, Pages 65-71

  Hare, C Bradley ^a   Kahn, James O ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOSPORIN A; CYTOKINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

DIAGNOSTIC PROCEDURE; DISEASE COURSE; ERADICATION THERAPY; EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPATHOGENESIS; MULTIDRUG RESISTANCE; NONHUMAN; PATHOLOGY; PATIENT CARE; PRIMARY INFECTION; PUBLIC HEALTH; REVIEW; SEXUAL BEHAVIOR; TREATMENT OUTCOME; VIREMIA; VIRUS RESISTANCE;

EID: 5144221620     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-004-0026-1     Document Type: Review

References (54)

1. Joint United Nations Programme on HIV/AIDS: Table of UNAIDS/WHO global and regional HIV/AlDS estimates end-2002. http://www.unaids.org/html/pub/Topics/Epidemiology/ RegionalEstimates2002_en_pdf.htm. Accessed October 1, 2003.
2. HIV incidence among young men who have sex with men - seven U.S. cities, 1994-2000. MMWR Morb Mortal Wkly Rep 2001, 50:440-444.
3. Shacker T, Collier AC, Hughes J, et al.: Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996, 125:257-264.
4. Cooper D, Cold J, Maclean P, et al.: Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1985; 1:537-540.
5. Vanhems P, Dassa C, Lambert J, et al.: Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. J Acquir Immune Defic Syndr 1999, 21: 99-106.
6. Kahn J, Walker BD: Acute human immunodeficiency virus type-1. N Engl J Med 1998, 339:33-40.
7. Hecht FM, Busch MP, Rawal B, et al.: Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS 2002, 16:1119-1129.
8. Pedersen C, Lindhardt BO, Jensen BL, et al.: Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 1989, 299:154-157.
9. Busch MP, Lee LL, Satten GA, et al.: Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors. Transfusion 1995, 35:91-97.
10. Fiebig EW, Wright DJ, Rawal BD, et al.: Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003, 17:1871-1879.
11. Janssen R, Satten G, Stramer S, et al.: New testing strategy to detect early HIV-1 infection for use in incidence estimates and for clinical and prevention purposes. JAMA 1998, 280: 42-48.
12. Spira AI, Marx PA, Patterson BK, et al.: Cellular targets of infection and route of viral dissemination following an intravaginal inoculation of SIV into rhesus macaques. J Exp Med 1996, 183:215-225.
13. Clark SJ, Saag MS, Decker WD, et al.: High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991, 324:954-960.
14. Zhu T, Mo H, Wang N, et al.: Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993, 261:1179-1181.
15. Roos M, De Leeuw N, Claessen F, et al.: Viro-immunological studies in acute HIV-1 infection. AIDS 1994, 8:1533-1538.
16. Musey L, Hughes J, Schacker T, et al.: Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection. N Engl J Med 1997, 337:1267-1274.
17. Pantaleo G, Demarest JF, Schacker T, et al.: The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia. Proc Natl Acad Sci USA 1997, 94:254-258.
18. Yang OO, Kalams SA, Trocha A, et al.: Suppression of human immunodeficiency virus type 1 replication by CD8+ cells: evidence for HLA class I-restricted triggering of cytolytic and noncytolytic mechanisms. J Virol 1997, 71:3120-3128.
19. Roos M, De Leeuw N, Claessen F, et al.: Viro-immunological studies in acute HIV-1 infection. AIDS 1994, 8:1533-1538.
20. Pilgrim AK, Pantaleo G, Cohen OJ, et al.: Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. J Infect Dis 1997, 176:924-932.
21. Mellors JW, Kingsley LA, Rinaldo, et al.: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995, 122:573-579.
22. Koopman JS, Jacquez JA, Welch GW, et al.: The role of early HIV infection in the spread of HIV through populations. J Acquir Immun Defic Syndr 1994, 7:1169-1184.
23. Erice A, Mayers DL, Strike DG, et al.: Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993, 328:1163-1165.
24. Hecht FM, Grant RM, Hellman N, et al.: Transmission of human immunodeficiency virus type-1 resistant to multiple reverse transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-311.
25. Little SJ, Daar ES, D'Aquila RT, et al.: Reduced antiviral drug susceptibility among patients with primary HIV infection. JAMA 1999, 282:1142-1149.
26. Balotta C, Berlusconi A, Pan A, et al.: Prevalence of transmitted nucleoside analogue-resistant HIV-1 strains and pre-existing mutations in pol reverse transcriptase and protease region: outcome after treatment in recently infected individuals. Antivir Ther 2000, 5:7-14.
27. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001, 322:1087-1088.
28. Boden D, Hurley A, Zhang L, et al.: HIV-1 drug resistance in newly infected individuals. JAMA 1999, 282: 1135-1141.
29. Little SJ, Holte S, Routy JP, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002, 347:385-394.
30. Yerly S, Vora S, Rizzardi P, et al.: Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS 2001, 15:2287-2292.
31. Grant RM, Hecht FM, Warmerdam M, et al.: Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA 2002, 288:181-188.
32. Wensing AMJ, Van de Vijver DAMC, Asjo B, et al.: Prevalence of transmitted drug resistance in Europe is largely influenced by the presence of non-B sequences: analysis of 1400 patients from 16 countries: the CATCH-study [abstract 117]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Cabos, Mexico: 2003:S131.
33. Routy JP, Brenner B, Rouleau D, et al.: Drug resistance prevalence declines in recently infected subjects having sex with men but not in those using drug infections: results from the Montreal Primary HIV-Infection Cohort [abstract 122]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S136.
34. Pillay D, Green H: The UK drug resistance database: development and use for national surveillance [abstract 124]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S138.
35. Bennett DE, Zaidi IF, Heneine W, et al.: Prevalence of mutations associated with antiretroviral drug resistance among men and women newly diagnosed with HIV in 10 US cities, 1997-2001 [abstract 119]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S133.
36. Jayaraman GC, Gleeson T, Sandstrom V, Archibald CP: The Canadian HIV strain and drug resistance program - a population-based effort to enhance HIV surveillance [abstract 121]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S135.
37. Grant RM, Liegler T, Spotts G, Hecht FM: Declining nucleoside reverse transcriptase inhibitor primary resistance in San Francisco, 2000-2002 [abstract 120]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S134.
38. Chaix ML, Descamps D, Mouajjah S, et al.: French National Sentinel Survey of antiretroviral resistance in patients with HIV-1 primary infection and in antiretroviral-naïve chronically infected patients in 2001-2002 [abstract 123]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico; 2003:S137.
39. Turner D, Brenner BG, Routy JP, et al.: Decreased rates of transmission of drug-resistant HIV-1 strains containing the M184V mutation in reverse transcriptase [abstract 129]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S143.
40. Deeks SG, Wrin T, Liegler T, et al.: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472-480.
41. Little SJ, Dawson K, Hellman NS, et al.: Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy [abstract 115]. Proceedings of the XII International Drug Resistance Workshop: Basic Principles and Clinical Implications 2003. Los Cabos, Mexico: 2003:S129.
42. Hirsch MS, Brun-Vezinet F, Clotet B, et al.: Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003, 37:113-128.
43. Markowitz M, Vesanen M, Tenner-Racz K, et al.: The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999, 179: 525-537.
44. Smith DE, Kaufman GR, Kahn JO, et al.: Greater reversal of CD4+ cell abnormalities and viral load reduction after initiation of antiretroviral therapy with zidovudine, lamivudine, and nelfinavir before complete HIV type 1 seroconversion. AIDS Res Hum Retroviruses 2003, 19:189-199.
45. Hecht RA, Hare CB, McGrath MS, et al.: Interleukin-2 (IL-2) in conjunction with HAART in early HIV infection increases naïve and memory CD4 cells and lowers activation markers [abstract 649]. Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections 2003. Boston: Foundation for Retrovirology and Human Health, NIAID, and CDC; 2003.
46. Rizzardi GP, Harari A, Capiluppi B, et al.: Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002, 109:681-688.
47. Markowitz M, Jin X, Hurley A, et al.: Discontinuation of antiretroviral therapy commenced early during the course of human immunodeficiency virus type 1 infection, with or without adjunctive vaccination. J Inject Dis 2003, 186:634-643.
48. Wasserman S: HIV/AIDS: partner notification programs. Issue brief. Health Policy Tracking Service; 2000.
49. Osborn JE. AIDS: politics and science. N Engl J Med 1988, 318:444-447.
50. Golden MR: HIV partner notification: a neglected prevention intervention. Sex Transm Dis 2002, 29:472-475.
51. Golden MR, Hogben M, Handsfield HH, et al.: Partner notification for HIV and STD in the United States: love coverage for gonorrhea, chlamydial infection, and HIV. Sex Transm Dis 2003, 30:490-496.
52. Kissinger PJ, Niccolai LM, Magnus M, et al.: Partner notification for HIV and syphilis: effects on sexual behaviors and relationship stability. Sex Transm Dis 2003, 30:89-90.
53. Hoxworth T, Spencer NE, Peterman TA, et al.: Changes in partnerships and HIV risk behavior after partner notification. Sex Transm Dis 2003, 30:83-88.
54. Landis SE, Schoenbach VJ, Weber DJ, et al.: Results of a randomized trial of partner notification in cases of HIV infection in North Carolina. N Engl J Med 1992, 326:101-106.